ClinicalTrials.gg
Enrolling by invitationNCT06820749Updated Feb 20, 2025

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion

A Phase 2 interventional study of HSK31858 and Placebo in Asthma Bronchiale, Bronchiectasis and Chronic Obstructive Pulmonary Disease (COPD), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Bronchiectasis with a site in China — 35 open to participants now, 38 under way, 4 of them phase 3. Bronchiectasis · China.

Planned enrollment
11th of 50
309 · median 120
Started
2024
with 8 others
Phase 2
10 of 84
5 open now
Primary completion
2026-04
later than 4 of 37 live
Registered
58th of 84
by date
Lead sponsor
7 of 84
Haisco Pharmaceutical Group Co., Ltd.

Among the 84 studies in Bronchiectasis with a site in China, this one is the 11th largest by planned enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 4 of the 37 other live ones, and was the 58th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

35 of the 84 studies in Bronchiectasis with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Bronchiectasis with a site in China, or all of them as a file.
02

Study summary

This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases

03

Conditions studied

  • Asthma Bronchiale
  • Bronchiectasis
  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1)Able to fully understand and voluntarily sign ; 2)Male or female patients ≥18 years of age at the time of screening; 3)Patient with chronic airway inflammatory diseases (bronchiectasis, , asthma); 4)24h sputum volume ≥10ml at screening period (V1) and baseline (V2); 5) If the subjects have used background therapy drugs, other background therapy drugs other than expectorant drugs were used to maintain stability for ≥1 month before screening; 6)Female subjects with fertility or male subjects whose partner is a female with fertility must agree to have no plans to have children and to use voluntarily from the time of signing the informed consent form until 3 months after the last dose. All females of must have a negative screening pregnancy test.

7)Subjects are able to communicate well with the investigator and are able to complete the study in accordance with the protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Known allergic history to the active ingredient of the drug or other drugs with similar chemical structure;
  2. accounted for less than 30% of the estimated value after bronchodilator use;
  3. Patients who have experienced any degree of acute exacerbation of asthma or are experiencing an acute exacerbation of asthma within 4 weeks prior to screening;
  4. Hemoptysis (other than a small amount of bloody sputum or a blood clot smaller than a fingernail) occurs within 4 weeks prior to screening and requires urgent medical intervention;
  5. Active infection or acute infection requiring systemic anti-infective therapy within 4 weeks prior to screening.
  6. History of : subjects with basal cell carcinoma, limited squamous cell carcinoma of the skin, or cervical carcinoma in situ will be allowed to enter the study if curative treatment has been completed for at least 12 months prior to signing the form; subjects with other malignancies will be allowed to enter the study if curative treatment has been completed for at least 5 years prior to signing the informed consent form;
  7. Presence of any severe and/or uncontrolled medical condition that, in the judgement of the investigator, affects the safety of the subject or interferes with the evaluation of the medication, including, but not limited to: severe neurological disease, history of serious mental disorders, major cardiovascular disease, diabetes mellitus that is poorly controlled on standardized therapy, presence of prolonged interval or cardiac arrhythmia, or immunodeficiency disorders;
  8. Subjects with a history of liver disease or currently receiving treatment for liver disease during the screening period, including but not limited to acute and chronic hepatitis, cirrhosis or liver failure;
  9. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg, and/or diastolic blood pressure ≥ 100 mmHg at screening or baseline);
  10. Abnormal screening and baseline laboratory tests:

    1. White blood cell count \< 3 × 109/L, or \< 1.5 × 109/L, or \< 70 × 109/L, or \< 90 g/L;
    2. (ALT) > 2 × (upper limit of normal), or aspartate aminotransferase (AST) > 2 × ULN, or total (TBIL) > 1.5 × ULN;
    3. Patients with moderate to severe renal insufficiency ( \< 60 ml/min/1.73m2, calculation of eGFR using the simplified MDRD equation);
  11. Participation in a clinical trial of any other drug or medical device (treated with a drug or medical device in a clinical trial) within 1 months prior to screening;
  12. Having received a drug that may cause hyperkeratosis of the skin (e.g., tumor necrosis factor alpha antagonist) within 4 weeks prior to screening;
  13. Patients who have used a strong inducer or inhibitor of within 14 days or 5 half-lives prior to the first investigational product administration, whichever is longer;
  14. Comorbidities associated with the development of non-hereditary palmoplantar keratoderma (e.g., myxedema, chronic lymphoedema);
  15. Comorbid periodontal disease that, in the judgement of the investigator, has an impact on the study;
  16. Asthmatic currently smoking subjects or subjects who quit smoking within 6 months prior to the screening visit; previous smoking subjects with a smoking history >10 pack-year = packs per day × years of smoking (Note: 1 pack = 20 cigarettes, 10 pack-year = 1 pack/day × 10 years or 1/2 pack/day × 20 years).
  17. History of drug use, or substance abuse within 2 years prior to screening;
  18. Pregnant, or planning to become pregnant during the study, or breastfeeding;
  19. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (estimated)

Study arms

  • Experimental
    HSK31858 20mg

    multiple oral doses: 20mg/d for 12w

    Drug: HSK31858

  • Experimental
    HSK31858 40mg

    multiple oral doses: 40mg/d for 12w

    Drug: HSK31858

  • Placebo comparator
    placebo

    multiple oral doses for 12w

    Drug: Placebo

Interventions

  • HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 12-week treatment period in patients with airway mucus hypersecretion in chronic airway inflammatory diseases

  • DrugPlacebo

    the placebo comparator of study

06

What researchers measure

Primary outcomes

  1. Change from baseline in 24 hour sputum weight

    Change from baseline in 24 hour sputum weight after 12 weeks of treatment

    Time frame: 12-week treatment period

Secondary outcomes

  1. Change from baseline in expectoration difficulty score

    Change from baseline in expectoration difficulty score after 4, 8 and 12 weeks of treatment.The expectoration difficulty score adopt a 4-level evaluation standard, 0 points for no expectoration, 1 points for easy expectoration, 2 points for moderate expectoration difficulty, and 3 points for hardest expectoration.

    Time frame: 12-week treatment period

  2. Change from baseline in sputum trait score

    Change from baseline in sputum trait score after 4, 8, and 12 weeks of treatment.The sputum trait score was based on the Miller classification, according to the proportion of purulent part to total sputum volume.

    Time frame: 12-week treatment period

  3. Change from baseline in sputum viscosity score

    Change from baseline in sputum viscosity score after 4, 8, and 12 weeks of treatment.The sputum viscosity score is based on a 5-level evaluation standard. Sputum adhering to the cup wall of the container and not sliding down is 1 point; sputum slowly sliding through the cup wall of the container under the action of gravity is 2 points; sputum sliding in large pieces through the cup wall under the action of gravity is 3 points; sputum is easily poured out and a small amount of thin mucus sticks to the cup wall of the container. No residual sputum on the wall of the container 5 points.

    Time frame: 12-week treatment period

  4. Change from baseline in cough severity score

    Change from baseline in cough severity score after 4, 8, and 12 weeks of treatment.The visual analog scale (VAS) was used to score the severity of cough: a line 10 cm long was drawn on the white paper, and the corresponding scale was marked to indicate the severity of cough. The score was 0 to 10 points, 0 was no cough and no trouble to the patient, and 10 was the most serious cough and the most serious trouble to the patient.

    Time frame: 12-week treatment period

  5. Change from baseline in cough and sputum assessment questionnaire

    Change from baseline in cough and sputum assessment questionnaire after 4, 8, and 12 weeks of treatment.The cough and sputum assessment questionnaire is an evaluation tool used to evaluate the impact of cough and sputum on the quality of life of patients. The contents involved four dimensions: cough symptoms, cough effects, sputum symptoms and sputum effects. Each dimension contained different items, which were scored and statistically converted, with a total score of 100 points. The lower the score, the heavier airway mucus hypersecretion.

    Time frame: 12-week treatment period

  6. Change from Baseline in forced expiratory volume in 1 second (FEV1)

    Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at 12 week.

    Time frame: 12-week treatment period

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Apr 2026, 16 months after the start.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 11, 2025
StartActual
Dec 10, 2024
Primary completionEst.
Apr 23, 2026
CompletionEst.
Jun 22, 2026
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06820749
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Dec 10, 2024
Primary completion
Apr 23, 2026 (estimated)
Completion
Jun 22, 2026 (estimated)
Last update
Feb 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florensocatib

Start the discussion